Beta Bionics Inc [BBNX] stock prices are down -0.38% to $18.43 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The BBNX shares have gain 4.42% over the last week, with a monthly amount drifted -36.86%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beta Bionics Inc [NASDAQ: BBNX] stock has seen the most recent analyst activity on January 09, 2026, when BofA Securities downgraded its rating to a Neutral. On October 01, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $26 on the stock. Truist started tracking the stock assigning a Buy rating and suggested a price target of $26 on June 16, 2025. Lake Street initiated its recommendation with a Buy and recommended $30 as its price target on June 12, 2025. Wolfe Research started tracking with a Outperform rating for this stock on May 30, 2025, and assigned it a price target of $20. In a note dated May 30, 2025, Goldman initiated an Neutral rating and provided a target price of $16 on this stock.
The stock price of Beta Bionics Inc [BBNX] has been fluctuating between $8.89 and $32.71 over the past year. Currently, Wall Street analysts expect the stock to reach $32.17 within the next 12 months. Beta Bionics Inc [NASDAQ: BBNX] shares were valued at $18.43 at the most recent close of the market. An investor can expect a potential return of 74.55% based on the average BBNX price forecast.
Analyzing the BBNX fundamentals
The Beta Bionics Inc [NASDAQ:BBNX] reported sales of 88.57M for trailing twelve months, representing a surge of 63.14%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at -0.77%, Pretax Profit Margin comes in at -0.88%, and Net Profit Margin reading is -0.88%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.32 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Beta Bionics Inc [NASDAQ:BBNX]’s Current Ratio is 10.64. On the other hand, the Quick Ratio is 9.83, and the Cash Ratio is 1.52. Considering the valuation of this stock, the price to sales ratio is 9.16, the price to book ratio is 2.75.
Transactions by insiders
Recent insider trading involved Mensinger Mike, Chief Product Officer, that happened on Jan 06 ’26 when 2200.0 shares were sold. Chief Product Officer, Mensinger Mike completed a deal on Jan 02 ’26 to sell 7800.0 shares. Meanwhile, Chief Financial Officer Feider Stephen sold 20000.0 shares on Jan 02 ’26.
